SMARCA2 and neoplasm: A single study has reported additional SWI/SNF complex member mutations in a small number of OCCC cases, specifically in both of the mutually exclusive ATPase subunits SMARCA4 (3 of 55 tumours) and SMARCA2 (1 of 55 tumours), as well as in the core scaffold subunit SMARCC1 (1 of 55 tumours) (Table 2) [17]. Furthermore, the loss of SMARCA4 detected by immunohistochemistry has been reported in between 2–5% of OCCC [26,92,112,113].